Pacific Biosciences
PACB
Pacific Biosciences (PACB) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.14
- EPS estimate
- −$0.14
- EPS surprise
- −2.41%
- Revenue surprise
- −0.50%
- Revenue
- $39.0M
- Revenue estimate
- $39.2M
- Reported
- Aug 5, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | −$0.14 | −$0.14 | −2.41% | $39.0M | SEC |
| Q1 2026 | May 7, 2026 | −$0.14 | −$0.03 | +78.83% | $37.2M | SEC |
| Q4 2025 | Feb 12, 2026 | −$0.14 | −$0.13 | +9.53% | $44.6M | SEC |
| Q3 2025 | Nov 5, 2025 | −$0.15 | −$0.13 | +14.02% | $38.4M | SEC |
| Q2 2025 | Aug 7, 2025 | −$0.17 | −$0.14 | +18.98% | $39.8M | SEC |
| Q1 2025 | May 8, 2025 | −$0.19 | −$1.44 | −652.35% | $37.2M | SEC |
| Q4 2024 | Feb 13, 2025 | −$0.19 | $0.01 | +105.19% | $39.2M | SEC |
| Q3 2024 | Nov 7, 2024 | −$0.22 | −$0.22 | +0.32% | $40.0M | SEC |
| Q2 2024 | Aug 7, 2024 | −$0.23 | −$0.64 | −174.68% | $36.0M | SEC |
| Q1 2024 | May 9, 2024 | −$0.28 | −$0.29 | −5.26% | $38.8M | SEC |
| Q4 2023 | Feb 15, 2024 | −$0.29 | −$0.31 | −8.05% | $58.4M | SEC |
| Q3 2023 | Oct 30, 2023 | −$0.29 | −$0.26 | +10.13% | $55.7M | SEC |
| Q2 2023 | Aug 2, 2023 | −$0.32 | −$0.28 | +12.50% | $47.6M | SEC |
| Q1 2023 | May 2, 2023 | −$0.33 | −$0.36 | −8.50% | $38.9M | SEC |
| Q4 2022 | Feb 16, 2023 | −$0.36 | −$0.37 | −2.69% | $27.4M | SEC |
| Q3 2022 | Nov 7, 2022 | −$0.33 | −$0.34 | −2.50% | $32.3M | SEC |
| Q2 2022 | Aug 3, 2022 | −$0.34 | −$0.32 | +5.41% | $35.5M | SEC |
| Q1 2022 | May 4, 2022 | −$0.32 | −$0.37 | −15.59% | $33.2M | SEC |
| Q4 2021 | Feb 15, 2022 | −$0.28 | −$0.31 | −9.42% | $36.0M | SEC |
| Q3 2021 | Nov 2, 2021 | −$0.22 | $0.08 | +136.04% | $34.9M | SEC |
Quarterly revenue
Frequently asked questions
When did Pacific Biosciences (PACB) last report earnings?
Pacific Biosciences last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did PACB beat earnings estimates?
No. Pacific Biosciences reported EPS of −$0.14 for Q2 2026 against a −$0.14 estimate — a 2.41% miss.
How much revenue did PACB report last quarter?
Pacific Biosciences reported $39.0M in revenue for Q2 2026, against a consensus estimate of $39.2M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.